随着经济发展伴随着生活方式改变,全球肥胖患者人群不断扩大,和消费者对于身材管理的重视,人们对减肥的需求不断上涨。GLP-1类药物凭借良好的安全性和减重效果,已逐渐成为减重赛道主流靶点。一、诺和诺德引领减肥革命2010年,诺和诺德(Novo nordisk)推出了首款GLP-1受体激动剂利拉鲁肽(Liraglutide),用于治疗2型糖尿病,在2014年获批肥胖适应症后,由GLP-1引领的减肥时代...
Source Link随着经济发展伴随着生活方式改变,全球肥胖患者人群不断扩大,和消费者对于身材管理的重视,人们对减肥的需求不断上涨。GLP-1类药物凭借良好的安全性和减重效果,已逐渐成为减重赛道主流靶点。一、诺和诺德引领减肥革命2010年,诺和诺德(Novo nordisk)推出了首款GLP-1受体激动剂利拉鲁肽(Liraglutide),用于治疗2型糖尿病,在2014年获批肥胖适应症后,由GLP-1引领的减肥时代...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.